Status:
COMPLETED
Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis
Lead Sponsor:
University Hospital, Tours
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation. Three studies have shown a c...
Detailed Description
Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation. Three studies have shown a c...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Patient with skin psoriasis (new and untreated or being treated, flare-up or stable, possibly bleached)
- Requiring a blood sample for disease or treatment monitoring
Exclusion
- History of invasive mucosal squamous cell carcinoma, or squamous cell carcinoma of the skin with lymph node or visceral recurrence.
- Patient under guardianship or curatorship
- Opposition to participation in the study
Key Trial Info
Start Date :
July 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 27 2022
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT04308616
Start Date
July 20 2020
End Date
April 27 2022
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Service, University Hospital, Tours
Tours, France, 37044